RAPPORT THERAPEUTICS INC.

Rapport Therapeutics Inc (RAPP) is a small‑cap biotechnology company with a market capitalisation around $1.23bn. Like many biotechs, its outlook is closely tied to the progress of its development pipeline, clinical trial readouts, regulatory milestones and any partnership or licensing agreements. Key indicators for investors include upcoming trial results, cash runway and financing activity, management experience and milestones that could trigger partnerships or revenue. Shares can be volatile and subject to binary outcomes where single clinical or regulatory events may cause material moves in price. That makes RAPP potentially higher risk and higher reward relative to established pharmaceutical companies. This summary is for general educational purposes only and is not personal financial advice; investors should assess suitability for their own circumstances and consider professional advice before investing. For the latest details, consult company filings and investor presentations.